Insider Trade: Jeffrey Chodakewitz Sold 3,696 Shares of Vertex Pharmaceuticals (VRTX); Commerce Group Has 0.57 Sentiment

Celadon Group, Inc., through its subsidiaries, provides transportation services between the United States, Canada, and Mexico. The company has market cap of $137.22 million. It operates through three divisions: Asset-Based, Asset-Light, and Equipment Leasing and Services. It has a 57.56 P/E ratio. The Asset-Based segment offers dry van, refrigerated, and flatbed services; cross-border services between the United States and each of Mexico and Canada; intra-Mexico and intra-Canada services; contract services; regional and specialized short haul services; and rail intermodal services.

Vertex Pharmaceuticals Inc Ma’s EVP GMDA – CMO Jeffrey Chodakewitz unloaded 3,696 shares of the Massachusetts-based company in a broker transaction dated 05/02/2018. These shares were unloaded at stock price per share of $166.8, for a cumulative trade value of $616,465. Jeffrey is trying to decrease his company’s share, same as he did in the last month. He unloaded another 1,719 shares worth $270,358 USD. Now, Jeffrey Chodakewitz owns 52,524 shares which are equivalent to exactly 0.02% of Vertex Pharmaceuticals Inc Ma’s market cap. For full analysis of this trade please refer to the U.S. Security & Exchange Commission’s Form 4 available for a free review here.

Among 30 analysts covering Vertex Pharmaceuticals (NASDAQ:VRTX), 26 have Buy rating, 0 Sell and 4 Hold. Therefore 87% are positive. Vertex Pharmaceuticals has $212.0 highest and $85.0 lowest target. $176.31’s average target is 13.65% above currents $155.14 stock price. Vertex Pharmaceuticals had 94 analyst reports since July 31, 2015 according to SRatingsIntel. The firm has “Overweight” rating by Morgan Stanley given on Friday, February 2. The company was maintained on Friday, June 9 by Jefferies. On Monday, August 17 the stock rating was upgraded by Vetr to “Hold”. The firm has “Buy” rating given on Tuesday, September 1 by Vetr. The firm has “Mkt Perform” rating given on Tuesday, September 13 by Raymond James. The company was maintained on Thursday, January 26 by Stifel Nicolaus. The firm earned “Market Outperform” rating on Friday, March 17 by JMP Securities. Maxim Group maintained it with “Buy” rating and $19500 target in Wednesday, July 19 report. The company was maintained on Thursday, April 28 by RBC Capital Markets. The firm earned “Neutral” rating on Monday, October 24 by H.C. Wainwright.

Vertex Pharmaceuticals Incorporated discovers, develops, makes, and commercializes medicines for serious diseases. The company has market cap of $39.24 billion. The firm focuses on developing and commercializing therapies for the treatment of cystic fibrosis and advancing its research and development programs. It has a 149.17 P/E ratio. It markets ORKAMBI (lumacaftor in combination with ivacaftor) for the treatment of patients with CF 12 years of age and older who have two copies (homozygous) of the F508del mutation in their cystic fibrosis transmembrane conductance regulator (CFTR) gene; and KALYDECO (ivacaftor) for the treatment of patients with CF 2 years of age and older who have the G551D mutation or other specified mutations in their CFTR gene.

Since August 7, 2017, it had 0 buys, and 27 sales for $102.07 million activity. The insider LEIDEN JEFFREY M sold $17.67 million. Graney Thomas sold 777 shares worth $116,511. On Wednesday, January 24 Arbuckle Stuart A sold $1.52M worth of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) or 8,969 shares. Sachdev Amit sold 46,172 shares worth $7.33 million. The insider Chodakewitz Jeffrey sold $521,198. The insider ALTSHULER DAVID sold $287,360. Silva Paul M sold 5,435 shares worth $891,487.

Investors sentiment increased to 1.62 in Q3 2017. Its up 0.11, from 1.51 in 2017Q2. It is positive, as 32 investors sold Vertex Pharmaceuticals Incorporated shares while 151 reduced holdings. 79 funds opened positions while 217 raised stakes. 231.42 million shares or 0.04% more from 231.33 million shares in 2017Q2 were reported. Eaton Vance Mngmt reported 647,503 shares. Westpac, Australia-based fund reported 76,052 shares. Weiss Asset Mngmt L P holds 1,663 shares or 0.03% of its portfolio. Boston Private Wealth Limited Com has invested 0.09% in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX). Nicholas Invest Ptnrs L P owns 40,051 shares for 0.42% of their portfolio. Gateway Invest Advisers Ltd Limited Liability Company reported 0.18% in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX). 9,991 are owned by Botty Lc. Aperio Limited Liability Co reported 0.08% in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX). Healthcor Mngmt L P has 34,950 shares. Citigroup holds 138,351 shares or 0.02% of its portfolio. Rhumbline Advisers holds 0.14% or 427,457 shares. Covington Cap Mgmt accumulated 75 shares. Mufg Americas Holdings Corp reported 70 shares. Parkside Finance Bankshares stated it has 0.02% in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX). First Citizens Comml Bank Trust reported 0.05% in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX).

The stock decreased 6.68% or $11.1 during the last trading session, reaching $155.14. About 2.91M shares traded or 79.88% up from the average. Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) has risen 45.69% since February 6, 2017 and is uptrending. It has outperformed by 28.99% the S&P500.

Litespeed Management L.L.C. holds 13.42% of its portfolio in Celadon Group, Inc. for 2.82 million shares. Towle & Co owns 2.21 million shares or 1.58% of their US portfolio. Moreover, Phoenix Investment Adviser Llc has 1.45% invested in the company for 276,712 shares. The Minnesota-based Sns Financial Group Llc has invested 0.64% in the stock. Penn Capital Management Co Inc, a Pennsylvania-based fund reported 830,203 shares.